EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study

Mingming Wang, Shuofeng Li, Guanhua Yu, An Zhang, Shikang Ding, Yihong Zhang, Shi Feng, Zixiang Zhou, Mingjian Piao, Weixuan Pan, Chengjie Li, Boyu Sun und 7 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-025-04259-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Mingming Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Ch…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bile Duct Neoplasms, Cholangiocarcinoma, Immune Checkpoint Inhibitors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences (CIFMS), National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors (ICIs) plus chemotherapy serve as the primary treatment for advanced intrahepatic cholangiocarcinoma (ICC), but they present limited effectiveness. This multicenter study intended to evaluate the feasibility of LRT plus ICIs, chemotherapy, and lenvatinib in patients with advanced ICC. METHODS: Patients receiving LRT-ICIs-Chemotherapy-Lenvatinib (LRT-ICI-Chemo-Len group, N = 66) or ICIs-Chemotherapy (ICI-Chemo group, N = 81) between April 2020 and May 2025 were enrolled. The study's outcomes included progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs). RESULTS: The LRT-ICI-Chemo-Len group showed notable enhancement in median PFS (9.9 months vs. 7.6 months, P = 0.004), median OS (20.9 months vs. 13.7 months, P = 0.004), objective response rate (ORR: 59.1% vs. 27.2%), and disease control rate (DCR: 93.9% vs. 84.0%). Conversion resection was performed in 8/66 (12.1%) in the LRT-ICI-Chemo-Len group, statistically higher than the 2.5% in the ICI-Chemo group. There was no statistically significant difference in the incidence of grade 3-4 AE between the LRT-ICI-Chemo-Len group (65.2%) and the ICI-Chemo group (56.8%) (P = 0.389). The most common grade 3-4 AE in the LRT-ICI-Chemo-Len group was myelosuppression. In the ICI-Chemo group, the most frequent grade 3-4 AE was myelosuppression. All AEs were manageable, with no grade 5 AE observed. CONCLUSIONS: Compared with the ICI-Chemo regimen, the LRT-ICI-Chemo-Len regimen significantly improved the prognosis of patients with advanced ICC. There was no significant difference in the incidence of grade 3-4 AEs between the two treatment regimens, and all AEs were manageable. This indicates that the LRT-ICI-Chemo-Len combination regimen is a feasible approach for the first-line treatment of advanced ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCholangiocarcinomaImmune Checkpoint InhibitorsPhenylurea CompoundsQuinolinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle Aged

Stichwörter der Autor:innen

ChemotherapyImmunotherapyIntrahepatic cholangiocarcinomaLocal-regional therapyTargeted therapy

Substanzen

Immune Checkpoint InhibitorslenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. chenxinyuan_pumc@163.com.
  • Department of Hepatobiliary and Pancreatic Surgery, China-Japan Friendship Hospital, Beijing, China. sunyongliang1982@hotmail.com.
  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. wenwen0605@163.com.

Förderung

  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Wang, M., Li, S., Yu, G., Zhang, A., Ding, S., Zhang, Y., Feng, S., Zhou, Z., Piao, M., Pan, W., Li, C., Sun, B., Li, J., Zhang, N., Chen, X., Sun, Y., Zhang, W., Zhu, Z., & Zhao, H. (2026). Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04259-x

Vancouver

Wang M, Li S, Yu G, Zhang A, Ding S, Zhang Y, et al. Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-025-04259-x

BibTeX
@article{Wang2026,
  author = {Wang, Mingming and Li, Shuofeng and Yu, Guanhua and Zhang, An and Ding, Shikang and Zhang, Yihong and Feng, Shi and Zhou, Zixiang and Piao, Mingjian and Pan, Weixuan and Li, Chengjie and Sun, Boyu and Li, Jiongyuan and Zhang, Nan and Chen, Xinyuan and Sun, Yongliang and Zhang, Wen and Zhu, Zhenyu and Zhao, Haitao},
  title = {Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-025-04259-x}
}
Kostenlos starten →